gbola amusa md cfa head hc research
sale trade et
sale trade et
viral news genet medicin wamd data fall short fail piii
highlight week septemb septemb neutral report data
optic phase trial gene therapi gt wet age-rel
macular degener despit mean central retin thick crt post
time intravitr ivt inject patient requir anti-vegf rescu inject mean bcva
etdr letter wide confid rang make market question result wonder
result consist use oral steroid steroid fulli taper see research
neutral announc pivot phase trial cancer-select gene therapi
 fc recurr high grade glioma rhgg miss primari secondari endpoint final analysi
report median overal surviv os month treatment arm compar month
standard care soc privat present joint bic
inhibitor intern congress genoa data cohort patient phase i/ii trial
gt hemophilia hemb factor ix activ stabl
week post-treat patient remain free bleed episod requir supplement
buy announc posit data phase studi cytomegaloviru cmv vaccin
 system secret mrna chikungunya antibodi use neutral antibodi epitheli cell
infect seroposit subject benchmark seroneg individu receiv
phase studi achiev titer month vaccin
vaccin cours importantli subject initi phase cohort receiv show dose-
respons neutral ab titer seroposit benchmark year post vaccin provid earli
signal durabl phase trial subject achiev serum antibodi level
g/ml anticip protect level subject receiv mg/kg achiev cmax g/
ml respect would project maintain level g/ml target week fibrocel scienc
unrat announc compani acquir castl creek pharmaceut hold privat castl creek
pay total approxim mm cash includ buy-out fibrocel outstand common stock well
repay debt financi instrument acquisit expect close
look forward septemb septemb septemb heart failur societi america meet
continu philadelphia agenda includ akcea therapeut unrat unrat
septemb european associ studi diabet easd host annual meet
barcelona spain program includ repres crispr buy septemb
european pediatr neurolog societi epn congress take place athen greec program includ
repres avexi novarti unrat compani axov gene therapi buy bluebird bio unrat
orchard unrat san raffael telethon institut gene therapi privat
weekli price move vivo genet medicin aav srna mrna vivo gene edit
upcom chardan genet medicin event contact chardan rsvp
octob cell gene meet host arm carlsbad ca
gene express human crispr case studi suggest safeti head clinic readout
pleas refer import disclosur inform regul analyst certif found page report
septemb scientist peke univers china publish new england journal medicin
nejm case studi ex vivo crispr genom edit disrupt gene allogen hematopoiet stem cell
transplant patient hiv infect acut lymphoblast leukemia studi accompani
editori car-t pioneer carl june repres knowledg public safety/efficaci crispr
treat hiv human protein co-receptor hiv entri cell cell individu certain
natur occur variant shown resist hiv infect inde allogen stem cell
transplant donor variant erad hiv viru reservoir hiv patient preclin
studi suggest engin variant gene could function similarli unrat
academ collabor conduct sever clinic studi zinc finger nucleas zfn -base
disrupt confer hiv resist also gene center crispr babi saga
rogu scientist jiankui announc perform germlin genom edit embryo result birth
twin girl varieti uncharacter new gene variant unclear implic hiv protect
current studi build prior work group disrupt gene effici human
hsc result resist hiv infect anim transplant model hla-match donor hsc
subject gene edit ex vivo prior transplant patient transplant edit hsc
repres cell bone marrow blood percent remain stabl month point
patient leukemia remiss low percent modifi cell suffici clear hiv infect
takeaway case report stabil edit cell fraction time us gener
posit signal suggest edit cell appear abl divid normal clear immun
system concern given report adapt immun nucleas addit lack detect
off-target edit includ chromosom rearrang long-rang delet whole genom sequenc
support idea crispr edit specif enough use therapeut set cours
patient low frequenc edit cell mean rare event may miss sequenc assay data
patient higher edit effici longer follow-up provid clearer pictur safeti profil
gene-edit therapi sever gene edit program use crispr nucleas clinic
expect better visibl safeti next year inde anticip earli human data gene edit
program hemoglobinopathi sangamo buy-rat crispr later year
adverum report data optic phase trial gt
wet post intravitr ivt inject singl dose vg/ey
 patient requir anti-vegf rescu inject compar baselin averag previou anti-vegf
inject averag year sinc diagnosi injections/year
 mean bcva etdr letter wide confid rang
 mean central retin thick crt
 dose-limit toxic system relat report mild
moder ocular advers event potenti relat report
note data answer question rais august research august research
left sever question unansw inde saw neg posit
neutral optic consist benefit thesi support septemb amusa
reduc price target review academ literatur suggest
result seen optic might consist use steroid oppos benefit gene therapi
exampl quot abstract verbatim giancipoli et al see doi result
broadli similar optic result
interest confirm steroid success taper cohort patient
downgrad neutral piii miss limit pipelin visibl septemb livshit
announc pivot phase trial cancer-select gene therapi
fc recurr high grade glioma rhgg miss primari secondari endpoint final analysi
studi design assumpt overal surviv os month power detect
treatment effect month report median os month treatment arm compar
month standard care soc mean under-perform treatment
arm over-perform control arm rel expect
page
result reduc po indic given current uncertainti around potenti
regimen indic limit visibl plan preclin program develop
believ fair valu stock trade cash compani evalu next step
therefor reduc price target downgrad neutral
announc posit data phase studi cytomegaloviru cmv vaccin
system secret mrna chikungunya antibodi
discuss data day new york citi
cmv show potenti best-in-class immunogen present day point
preced commerci potenti clinic impact cite hpv rubella vaccin respect phase ii
studi set initi near term engag regul phase paramet
chikungunya data illustr point system deliveri mrna achiev high
therapeut protein express preclin protein express level correl level human
within immuno-oncolog i/o franchis reiter strateg focu boost respons anti-pd-
agent use complementari strategi therapeut vaccin immune-stimul new data
report oncolog program compani clinical-stag i/o program continu dose patient
genet medicin news septemb septemb
prqr buy receiv fda track design aso tx adrp septemb
phio unrat announc i/o collabor carisma tx privat sd-rxrna car-m septemb
adap unrat receiv fda odd spear t-cell target soft tissu sarcoma septemb
freelin privat announc updat data pi/ii trial aav-bas gt hemb septemb
freelin present joint bic inhibitor intern congress genoa itali data cohort
patient b-amaz phase i/ii trial gt hemb trial
conduct collabor ucl
patient treat singl iv infus low dose vg/kg activ reach
steadi state week respect evid inject site reaction
patient remain free spontan bleed latest time point neither requir supplement
recal juli freelin present data b-amaz trial show activ
updat data show durabl treatment recent time point
note previous dose escal trial on-going freelin target level rang
addit uniqur buy chardan top pick develop gt also
use gain-of-funct fix-padua variant juli present data phase iib trial show mean
activ week post-treat patient receiv dose vc/kg
unrat announc discontinu mrna tx over-the-counter defici septemb
unrat publish data pi/ii trial produc process fa septemb
announc public natur medicin data fancolen-i phase i/ii trial
ex vivo lentivir gt treatment fanconi anemia fa data trial
previous present asgct april
patient age treat iv administr fresh cryopreserv ex vivo modifi
hematopoiet stem/progenitor cell hspc without precondit treatment associ
favor safeti profil patient highest level gene mark arrest progress bone marrow
failur seen phenotyp correct patient measur resist dna cross-link agent
correl level gene mark
trial produc use process rocket sinc optim manufactur process
 order improv transduct vector copi number current futur trial use optim
process rocket plan announc initi data phase trial trial use
optim process
passag privat announc new gt develop program treat septemb
windmil tx privat appoint dr urvashi patel vice-president regulatori qualiti system septemb
buy present icpp addit data pi/ii piii trial rnai tx givosiran ahp septemb
page
trucod gene repair privat launch mm seri pna-bas gene edit septemb
unrat announc delay pi/ii trial gaucher diseas quarter septemb
nch publish pi trial hsv-base oncolyt viru seprehvir extracrani solid cancer septemb
genethon privat publish pre-exist anti-aav immun gt crigler najjar septemb
wizp unrat announc exclus licens w/copernicu tx privat non-vir gt chm septemb
cyad unrat announc price mm offer common stock septemb
genenta privat announc close mm fund round cancer septemb
unrat announc stock ad russel index septemb
 buffalo publish self-inactiv system reduc off-target edit septemb
unrat announc price mm offer common stock septemb
upenn publish engin cell approach treat cardiac fibrosi septemb
sln gb unrat report result provid corpor updat septemb
case western publish non-vir nanoparticle-bas gt approach stargardt diseas septemb
rgl unrat publish preclin data oligonucleotid adpkd septemb
unrat announc chang board director septemb
peke univers publish data patient treat crispr-edit hspc hiv septemb
unrat announc agreement amri privat mrna manufactur septemb
akouo privat announc gt program ak-otof snhl due otof mutat septemb
fcsc unrat announc acquisit castl creek privat mm septemb
fibrocel scienc announc compani acquir castl creek pharmaceut hold acquisit
expect close
castl creek pay total approxim mm cash includ fibrocel outstand common stock
well repay debt financi instrument acquisit price repres
premium fibrocel volum weight averag price septemb
acquisit follow castl creek fibrocel april announc collabor fibrocel
lead ex vivo lentivir gt candid treatment recess dystroph epidermolysi bullosa rdeb
fibrocel also develop ex vivo lentivir gt treatment moder sever local scleroderma
freelin privat dose patient pi/ii trial aav-bas gt fabri diseas septemb
navega tx privat receiv phase sbir grant develop gt cancer pain septemb
ortx unrat announc chief commerci offic jason meyenburg step septemb
gemini tx privat announc appoint jason meyenburg ceo septemb
compani mention report
page
page
select catalyst genet medicin coverag
dose patient phase studi mp
provid updat phase i/ii studi hemophilia
aro-aat initi phase ii/iii studi liver diseas
lumasiran initi illuminate-c phase trial
file ind pomp diseas
inclisiran report top-line data orion studi hypercholesterolemia
initi phase i/ii clinic trial huntington diseas
initi phase ii trial /- cemiplimab cutan squamou cell carcinoma
initi phase trial /- solid tumor
initi phase i/ii trial dmd nationwid children hospit
report interim efficaci readout phase oval trial ovarian cancer
report dose escal data pi/ii trial achm/xlrp
dcr-hbv anticip first interim data clinic trial hbv
provid initi data phase trial gangliosidosi
provid initi data phase trial gangliosidosi
axo-lenti-pd report data cohort sunrise-pd phase ii trial
submit ind methylmalon acidemia mma
present data phase portion solid tumor trial /- nivolumab
provid earli data cohort phase i/ii pioneer trial n- rp
file ind phase ii studi diabet retinopathi dr
present interim data pi/ii studi mp ii pi studi mp
present interim data cohort steroid prophyl pi/ii studi hofh
file ind batten diseas
top-lin phase ii data treat deb patient chronic wound
initi dose phase trial hemophilia
provid updat priorit program sjogren syndrom al wet
initi patient dose brillianc phase i/ii trial
report result phase i/ii ignit dmd trial
initi phase iib studi wet
lumasiran present top-line data illuminate-a phase trial
vutrisiran initi helios-b phase studi cardiomyopathi attr amyloidosi
inclisiran file nda hypercholesterolemia
file ind huntington diseas program
present preclin data new gt program fabri pomp defici
provid follow-up data piib dose-confirm studi hemb
file ind cta pomp diseas
present top-lin data phase i/iia clinic trial wet
declar develop candid aml
initi phase trial dystroph epidermolysi bullosa deb
figur alnylam/mdco meiragtx replimun solid uniqur expect import data read-out
page
select catalyst outsid genet medicin coverag
nsr-rpgr provid prelim data expans cohort phase ii/iii trial xlrp
dtx provid phase i/ii cohort data ornithin transcarbamylas defici
zolgensma anticip approv eu
nsr-rpgr report follow-up data open label dose escal phase xiriu studi
valrox submit bla pend fda feedback hemophilia
initi pivot phase trial rdeb
initi phase data patient leukocyt adhes deficiency-i lad-i
report initi phase data process fanconi anemia
suvodirsen interim data open-label extens studi dmd
initi phase studi pyruv kinas defici pkd
initi us phase ii studi fanconi anemia
initi phase i/ii trial parkinson diseas mutat
begin dose patient investigator-sponsor phase i/ii trial cystinosi
initi phase i/ii trial type gaucher diseas
bmn file ind phenylketonuria pku
initi phase ib trial beta-thalassemia
initi phase trial multipl myeloma
initi clinic trial charcot-marie-tooth type
file approv transit clinic trial platform manufactur
micro-dystrophin initi pivot trial duchenn muscular dystrophi
initi phase ii studi overact bladder
initi phase i/ii trial gangliosidosi
zolgensma complet strong phase trial pre-symptomat sma type
initi phase i/ii studi best diseas
micro-dystrophin initi confirmatori trial commerci materi dmd
begin patient dose phase trial
nsr-rpgr provid follow-up data phase xiriu dose escal studi xlrp
file ind inherit amyotroph later sclerosi
tegsedi expect approv brazil hattr amyloidosi
 anticip data readout phase trial hd
ptc-aadc file bla aromat l-amino acid decarboxylas aadc defici
ptc-fa file ind friedreich ataxia fa enter clinic
sea-bcma report preliminari phase dose escal data r/r mm
lentiglobin initi phase studi sickl cell diseas
zynteglo initi roll bla submiss fda tdt
report initi data phase i/ii trial phenylketonuria pku
rituximab report preliminari phase cohort data r/r nhl
figur plan file bla aadc defici
page
corpor report factset chardan note mention stock unrat unless state select public gm compani includ adhera therapeut
benitec biopharma buy lysogen oncosec medic oxford biomedica neutral vbl neutral
figur select price movement week end sep vivo gm perform aav srna mrna ivg
page
week-over-week perform vivo genet medicin aav srna mrna vivo gene edit basketstickerratingccm ptupsideclosechang changemc mm genet medicin cap genet medicin vivo cap genet medicin ex vivo cap gene therapytickerratingccm ptupsideclosechang changemc mm rocket genet therapytickerratingccm ptupsideclosechang changemc mm arbutu gene editingtickerratingccm ptupsideclosechang changemc mm precis pharmaceut
vivo genet medicin monthli market cap progress select compani
corpor report factset chardan note though avx nite acquir continu includ exhibit reflect valu creation sub-sector
figur aav-bas gene therapyend-monthli market cap select compani januari present
figur srna mrna therapyend-monthli market cap select compani januari present
figur vivo gene editingend-monthli market cap select compani januari present
page
cap million aav gt sector market cap cap million srna mrna gt sector market cap cap million vivo gene edit sector market cap pharmaceut
aav-bas gene therapi comp meiragtx uniqur chardan top pick
corpor report factset chardan note mention stock unrat unless otherwis state target market cap unrat name model current market cap
refer partner product avexi novarti compani wet hofh mp mp ii phase i/ii trial
figur select public aav-bas gene therapi companiesw prefer buy buy qure buy greater potenti drive upsid aav gt space
page
targettargetccmphas ofpriceccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof genet technolog privat aav-bas genetherapi molecular ask estev horama stride tamid technolog
srna mrna therapi comp alnylam top pick
corpor report factset chardan note mention stock unrat unless state target market cap unrat name model current market cap
figur select public srna mrna therapi companiesw prefer buy buy greater potenti drive upsid entir srna mrna space
page
targettargetccmphas ofpriceccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof profitalnylam privat srna mrna therapi companiesadvirna silense sirnaom somagen sylenti ntech curevac ethri etherna immunotherapi genev scienc strand note adhera benitec pharma silenc addit pharmaceut
vivo gene edit comp see greater upsid potenti intellia toolgen
corpor report factset chardan note mention stock unrat unless otherwis state target market cap unrat name model current market cap
figur vivo gene editingw broadli expect out-performance crispr sector higher potenti perform buy toolgen buy
page
targettargetccmphas ofpriceccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof profitcrispr privat vivogen edit companiesbeam egenesi excis exon feldan recombinet technolog pharmaceut
genet medicin therapeut approv posit opinion fda and/or ema
date
date
corpor report fda ema chardan note market author glybera expir due uniqur decis appli renew exclud antisens oligonucleotid figur
figur believ recent increas rate approv posit opinion genet medicin sign sector rapidli emerg
page
genet medicin therapeut receiv fda breakthrough therapi ema prime design
date fda btd
date ema prime
hattr amyloidosi polyneuropathi
corpor report fda ema biopharm insight chardan note ema start grant prime design may fda start grant breakthrough therapi design juli
figur believ disproportion amount btd prime design award genet medicin anoth sign sector rapidli emerg
page
date fda rmat
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur regen medicin advanc therapi design allow compani interact fda earlier clinic test process frequent
prioriti review voucher prv valu prv sold compani compani
date prv sale
swedish orphan biovitrum astrazeneca
ultragenyx undisclos
spark
ultragenyx novarti
biomarin undisclos
sarepta gilead
unit abbvi
sanofi
knight gilead
biomarin sanofi/regeneron pharmaceut
figur prioriti review voucher prv sold million million
price prv
page
date fda rpdd
corpor report fda biopharm insight chardan note list rpdd may incomplet sinc exampl compani disclos regulatori design
figur sinc pediatr diseas design potenti lead prioriti review voucher drug approv hidden sourc valu exist compani
ultragenyx genetx
page
date fda ftd
crispr vertex
crispr vertex
parkinson diseas mutat
rp due mutat exon gene
moder sever local scleroderma
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur track design facilit develop process expedit review drug seriou condit unmet medic need
page
date fda ftd
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur track design facilit develop process expedit review drug seriou condit unmet medic need
page
genet medicin select therapeut receiv btd rmat prime rpdd and/or ftd us eu
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
genetx ultragenyx
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
parkinson diseas mutat
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
genet medicin regulatori design btd rmat prime ftd rpdd grant time
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design ema start grant prime design may
fda start grant breakthrough therapi design btd juli pediatr diseas design rpdd rmat design genet medicin began novemb
figur regulatori design btd rmat prime ftd rpdd grant genet medicin consider increas grant
page
designationsyear design grantedgenet medicin regulatori design ytd btdrmatprimeftdrpdd biotechnolog pharmaceut
